You are now leaving the Lilly Medical Education website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical Education.
Important Considerations for Treatment Sequencing in CLL
This video discusses the importance of sequencing therapies based on patient-specific factors. cBTKi and/or BCL-2i are SOC 1L treatment options. BCL-2i, cBTKi, and ncBTKi are all possible treatment options in the 2L setting.
Date of Last Review: January 21, 2026
Document Number: VV-MED-167879
Related Resources
This infographic explores treatment sequencing strategies for patients with CLL, highlighting the influence of multiple clinical, disease, and patient factors on treatment selection and sequencing.
This infographic includes when to treat CLL based on iwCLL criteria, identifying disease progression, and a CLL treatment algorithm.
This short video discusses clinical decision-making in CLL treatment focusing on maximizing efficacy and minimizing adverse events by carefully determining when to start, hold, continue, or discontinue therapy.
This infographic discusses when to stop or start treatment in CLL based on disease activity, treatment response, and adverse events, aligning with iwCLL criteria.
This slide deck discusses when to start, stop, or switch CLL treatments based on disease activity, adverse events, and patient-centered decision-making to optimize outcomes.
This video discusses the importance of distinguishing between disease progression and treatment intolerance in CLL to guide appropriate therapy choices and optimize patient outcomes.
This slide deck outlines how to distinguish and manage treatment intolerance vs disease progression in CLL using diagnostic tools, multidisciplinary care, and shared decision-making to optimize patient outcomes.
This infographic outlines how to differentiate disease progression from treatment intolerance in CLL.
This infographic illustrates a real-world, case-based approach to navigating treatment decisions and disease progression in CLL, emphasizing personalized therapy selection and ongoing patient monitoring.
This slide deck reviews the types of efficacy assessments used in CLL clinical trials and routine practice, and how these assessments inform clinical decision making based on the specific CLL therapy administered.
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied